GERON CORP Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- GERON CORP share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 217.84K shares.
- GERON CORP share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 465.83K shares.
- GERON CORP share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-06-30 was 465.32K shares.
- GERON CORP share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-03-31 was 126.00K shares.
- GERON CORP share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 1.27M shares, a 92.88% decline from fiscal 2024.
- GERON CORP share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 17.91M shares, a 101.91% increase from fiscal 2023.
- GERON CORP share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 8.87M shares, a 650.55% increase from fiscal 2022.
- GERON CORP share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 1.18M shares, a 161.53% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-12-31 | 217.84K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | 1.27M shares 10-K · filed 2026-03-02 |
| 2025-09-30 | 465.83K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | |
| 2025-06-30 | 465.32K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | |
| 2025-03-31 | 126.00K shares 10-Q · filed 2025-05-07 | |
| 2024-12-31 | 17.91M shares 10-K · filed 2025-02-27 | |
| 2023-12-31 | 8.87M shares 10-K · filed 2024-02-28 | |
| 2022-12-31 | 1.18M shares 10-K · filed 2023-03-16 | |
| 2021-12-31 | 451.85K shares 10-K · filed 2022-03-10 | |
| 2020-12-31 | 21.94K shares 10-K · filed 2021-03-11 | |
| 2019-12-31 | 137.33K shares 10-K · filed 2020-03-12 | |
| 2018-12-31 | 3.14M shares 10-K · filed 2019-03-07 | |
| 2018-09-30 | 3.14M shares 10-Q · filed 2018-11-01 | |
| 2017-12-31 | 12.50K shares 10-K · filed 2018-03-16 | |
| 2016-12-31 | 328.49K shares 10-K · filed 2017-03-01 | |
| 2015-12-31 | 1.07M shares 10-K · filed 2016-03-10 | |
| 2014-12-31 | 662.63K shares 10-K · filed 2015-03-11 | |
| 2013-12-31 | 1.96M shares 10-K · filed 2014-03-17 | |
| 2012-12-31 | 417.00 shares 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |